Table 5 Presence of extended spectrum beta-lactamase (ESBL) resistance genes in the first year of life
Number of subjects# | Presence | Number of subjects* | Presence | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
Extended Spectrum Beta-lactamases | W3 | W3 and M12 | W3 and M12 | W3 | W3 to M3 | W3 to M6 | W3 to M12 | W3 to M3 | W3 to M6 | W3 to M12 |
blaTEM-1b | 9 | 6 | 67% | 2 | 2 | 2 | 1 | 100% | 100% | 50% |
blaSHV-1 | 8 | 1 | 13% | 2 | 0 | 0 | 0 | 0% | 0% | 0% |
blaSHV-11 | 3 | 0 | 33% | 1 | 1 | 0 | 0 | 100% | 0% | 0% |
blaSHV-142 | 1 | 0 | 0% | 1 | 0 | 0 | 0 | 0% | 0% | 0% |
blaSHV-83 | 1 | 0 | 0% | 1 | 0 | 0 | 0 | 0% | 0% | 0% |
blaOXA-116 | 1 | 0 | 0% | 1 | 0 | 0 | 0 | 0% | 0% | 0% |
blaOXA-347 | 2 | 2 | 100% | 1 | 1 | 1 | 1 | 100% | 100% | 100% |